a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Phase 3
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Neoplasms
Female
Breast Neoplasms
Trial Information
a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Inclusion Criteria
Inclusion Criteria
1. Locally advanced or metastatic breast cancer
2. Bi-dimensionally measurable disease
Exclusion Criteria
1. Prior hormonal therapy
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
3883
NCT ID:
NCT00034125
Start Date:
Completion Date:
Related Keywords:
- Breast Neoplasms
- cancer
- metastatic breast cancer
- hormonal therapy
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|---|
| Miami, Florida 33176 | |
| Nashville, Tennessee 37203-1632 | |
| Metairie, Louisiana 70006 | |
| Boston, Massachusetts |
